CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response
Related Experiment Video
Updated: Sep 1, 2025

A Screening Method for Identification of Heterochromatin-Promoting Drugs Using Drosophila
Published on: March 12, 2020
Cindy Wavelet-Vermuse1, Olena Odnokoz1, Yifan Xue2
1Department of Pharmacology and Chemical Biology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract:
Cell division cycle 20 (CDC20) functions as a critical cell cycle regulator. It plays an important role in cancer development and drug resistance. However, the molecular mechanisms by which CDC20 regulates cellular drug response remain poorly understood. Chromatin-associated CDC20 interactome in breast cancer cells was analyzed by using affinity purification coupled with mass spectrometry. hnRNPU as a CDC20 binding partner was validated by co-immunoprecipitation and immunostaining. The molecular domain, comprising amino acid residues 461-653, on hnRNPU required for its interaction with CDC20 was identified by mapping of interactions. Co-immunoprecipitation showed that CDC20-mediated hnRNPU ubiquitination promotes its interaction with the CTCF and cohesin complex. The effects of CDC20-hnRNPU on nuclear size and chromatin condensation were investigated by analyzing DAPI and H2B-mCherry staining, respectively. The role of CDC20-hnRNPU in tumor progression and drug resistance was examined by CCK-8 cell survival and clonogenic assays. Our study indicates that CDC20-mediated ubiquitination of hnRNPU modulates chromatin condensation by regulating the interaction between hnRNPU and the CTCF-cohesin complex. Dysregulation of the CDC20-hnRNPU axis contributes to tumor progression and drug resistance.
Insights
Cell division cycle 20 (CDC20) regulates chromatin condensation by ubiquitylating hnRNPU, impacting cancer progression and drug resistance. This CDC20-hnRNPU axis is crucial for tumor development.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- Cell division cycle 20 (CDC20) is a key regulator of the cell cycle.
- CDC20 is implicated in cancer development and drug resistance.
- The precise mechanisms of CDC20 in cellular drug response are not fully understood.
Purpose of the Study:
- To investigate the molecular mechanisms of CDC20 in regulating cellular drug response.
- To identify CDC20 interacting partners in breast cancer cells.
- To elucidate the role of the CDC20-hnRNPU interaction in tumor progression and drug resistance.
Main Methods:
- Affinity purification coupled with mass spectrometry to identify CDC20 interactome.
- Co-immunoprecipitation and immunostaining to validate protein interactions.
- DAPI and H2B-mCherry staining to assess nuclear size and chromatin condensation.
- CCK-8 and clonogenic assays to evaluate tumor progression and drug resistance.
Main Results:
- hnRNPU was identified as a novel binding partner of CDC20.
- CDC20-mediated ubiquitination of hnRNPU enhances its interaction with CTCF and cohesin complex.
- The CDC20-hnRNPU interaction modulates chromatin condensation, nuclear size, and impacts tumor progression.
- Dysregulation of the CDC20-hnRNPU axis correlates with increased tumor progression and drug resistance.
Conclusions:
- CDC20-mediated ubiquitination of hnRNPU is a critical mechanism for modulating chromatin condensation.
- The CDC20-hnRNPU axis plays a significant role in breast cancer progression and acquired drug resistance.
- Targeting the CDC20-hnRNPU pathway may offer novel therapeutic strategies for cancer treatment.
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Anaphase Promoting Complex
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Epigenetic Regulation
X-chromosome...

